deltatrials
Terminated PHASE2 NCT00107666

CTI-01 (Ethyl Pyruvate) Safety and Complication Prevention in Cardiac Surgery Patients on Cardiopulmonary Bypass (CPB)

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Proof of Concept Clinical Study of CTI-01 in Patients Undergoing Major Cardiac Surgery With Cardiopulmonary Bypass

Sponsor: Critical Therapeutics

Conditions Coronary Disease Heart Valve Diseases
Interventions CTI-01 (ethyl pyruvate)
Updated 6 times since 2017 Last updated: Mar 15, 2006 Started: Apr 30, 2005 Completion: Apr 30, 2006

Listed as NCT00107666, this PHASE2 trial focuses on Coronary Disease and Heart Valve Diseases and remains terminated or withdrawn. Sponsored by Critical Therapeutics, it has been updated 6 times since 2005, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Change History

6 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  4. Jan 2021 — Jul 2024 [monthly]

    Terminated PHASE2

  5. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE2

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Terminated PHASE2

    First recorded

Apr 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Critical Therapeutics
Data source: Critical Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Durham, United States, Gainesville, United States, Greenville, United States, Houston, United States, Laguna Hills, United States, Los Angeles, United States, Milwaukee, United States, New York, United States, Omaha, United States, Philadelphia, United States and 7 more location s